Structured evidence table for Chromium Insulin Sensitivity Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Chromium Insulin Sensitivity Meta-Analysis | Chromium supplementation has been associated with encouraging improvements in insulin sensitivity. | 1 | Babakr AT (2026) | Chromium as a Modulator of Insulin Receptor Activity: A Systematic Review of Its Role in Metabolic Syndrome and Type 2 Diabetes. |
| Chromium Insulin Sensitivity Meta-Analysis | This comprehensive review delves into the implications of chromium supplementation, particularly chromodulin, in the context of MetS and its associated pathological sequelae. | 1 | Babakr AT (2026) | Chromium as a Modulator of Insulin Receptor Activity: A Systematic Review of Its Role in Metabolic Syndrome and Type 2 Diabetes. |
| Chromium Insulin Sensitivity Meta-Analysis | In conclusion, chromium (Cr) enhances insulin sensitivity by directly activating the insulin receptor kinase, which lowers the required insulin concentration for maximal cellular response and improves glucose uptake and storage. | 1 | Babakr AT (2026) | Chromium as a Modulator of Insulin Receptor Activity: A Systematic Review of Its Role in Metabolic Syndrome and Type 2 Diabetes. |
| Chromium Insulin Sensitivity Meta-Analysis | Metabolic syndrome (MetS) is a complex interplay of interrelated metabolic derangements, including insulin resistance, dyslipidemia, central adiposity, and hypertension, thereby markedly amplifying the predisposition to type 2 diabetes mellitus (T2DM) and cardiovascular morbidities. | 1 | Babakr AT (2026) | Chromium as a Modulator of Insulin Receptor Activity: A Systematic Review of Its Role in Metabolic Syndrome and Type 2 Diabetes. |
| Chromium Insulin Sensitivity Meta-Analysis | Mineral supplementation was associated with significant reductions in fasting blood glucose (SMD = − 0.34, p < 0.001), fasting insulin (SMD = − 0.72, p < 0.001), and HOMA-IR (SMD = − 0.75, p < 0.001). | 1 | Ye J (2026) | Effectiveness of mineral supplements (magnesium, chromium, zinc, selenium, chromium picolinate) in reducing insulin resistance in polycystic ovary syndrome: a meta-analysis of randomized controlled trials. |
| Chromium Insulin Sensitivity Meta-Analysis | In addition, total cholesterol (SMD = − 0.35, p < 0.001) and triglyceride levels (SMD = − 0.58, p < 0.001) were significantly reduced. | 1 | Ye J (2026) | Effectiveness of mineral supplements (magnesium, chromium, zinc, selenium, chromium picolinate) in reducing insulin resistance in polycystic ovary syndrome: a meta-analysis of randomized controlled trials. |
| Chromium Insulin Sensitivity Meta-Analysis | CONCLUSION: Mineral supplementation may improve insulin resistance and selected metabolic parameters in PCOS, with the most consistent effects observed for glycemic indices. | 1 | Ye J (2026) | Effectiveness of mineral supplements (magnesium, chromium, zinc, selenium, chromium picolinate) in reducing insulin resistance in polycystic ovary syndrome: a meta-analysis of randomized controlled trials. |
| Chromium Insulin Sensitivity Meta-Analysis | BACKGROUND: Polycystic ovary syndrome (PCOS) often leads to insulin resistance, affecting glucose and fat metabolism. | 1 | Ye J (2026) | Effectiveness of mineral supplements (magnesium, chromium, zinc, selenium, chromium picolinate) in reducing insulin resistance in polycystic ovary syndrome: a meta-analysis of randomized controlled trials. |
Source documents